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1. Introduction
Infective endocarditis (IE), reflecting infections of the heart—as manifested by vegetations on
the valvular structures, abscess cavities of the myocardium, invasive fistula, or infections on
intracardiac prosthetic devices—represents a significant problem that continues to challenge
clinicians. The epidemiology of infections reflects not only the dark side of the progresses in
medical  therapy  but  also  some of  the  social  problems  that  plague  modern  society.  The
changing microbiology also reflects how this complex disease has also paralleled the advances
in medicine. Diagnostic tools continue to evolve with not only improvements in imaging
technologies  but  also  our  understandings  on  how  to  appropriately  use  them  to  better
understand the overall clinical picture. In addition, the role of therapies—especially early
surgical  intervention—has  been  demonstrated  to  have  a  significant  impact  on  the
management and outcomes of infected patients. The goal of this text is to highlight some of
the current concepts in the clinical characteristics, presentation, diagnosis, and management
options.
2. Epidemiology
The incidence of infectious endocarditis, without a doubt, has increased significantly over the
years. The reasons for this are multifactorial and reflect the growing number of patients who
are at risk due to their comorbidities. The list of comorbidities is extensive and includes
advancing age, chronic immunosuppression, end-stage renal failure, and those with pre-
existing intracardiac pathology. Furthermore, as patients are living longer and longer with
more complex comorbidities, medical teams are seeing the pathological consequences of some
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of the therapies that such patients require to prolong their lives. The dramatic increase in the
use of cardiac support devices, such as pacemaker, defibrillators, intravascular monitoring
devices, and left ventricular assist devices has presented unique and difficult challenges in
management when patients are clinically dependent on them and then they become infected
and may need to be removed. Clearly, endocarditis is one of those opportunistic problems that
result from medical advances. However, without doubt, the largest populations of patients
developing endocarditis are those with a history of intravenous drug abuse or those with a
history of implanted cardiac devices [1, 2]. The undeniable worldwide epidemic of intravenous
drug abuse has resulted in a dramatic increase in the incidence of younger patients presenting
with polymicrobial  invasive infections—often in the setting of  overwhelming sepsis  and
difficult  to manage social  situations with established concerns of  noncompliance.  In this
patient population, the primary cardiac infections might be the easiest of their presenting
problems to manage long term. The other major patient population at significant risk is those
with underlying cardiovascular pathologies requiring implantable support devices and lead
system. In addition, the increasing long-term survival of patients with prosthetic heart valves,
corrected congenital heart disease, and wider use of percutaneously implanted cardiac valves
(i.e., TAVR) or repair devices (i.e., mitral clips) in high-risk surgical patients also place these
patients at risk for device-related infection and the increasing incidence of endocarditis [3]. It
is  also  becoming concerning,  as  discussed in  this  text,  that  infections  in  certain  patient
populations—such as  those  with  end-stage  renal  disease  requiring hemodialysis—are  at
substantial risk for endocarditis and life-threatening complications in ways that are only
recently  being  appreciated  and  described  in  the  literature.  Nevertheless,  guidelines  for
prophylactic antibiotics remain unclear in how “at risk” patients should be managed at the
time of invasive procedures that might predispose to bacteremia and subsequent seeding of
cardiac, native and prosthetic, structures [4–6]. To say that there is much controversy in this
area is an understatement.
3. Microbiology
The microbiology of IE has also evolved over the years. The growing incidence of difficult-to-
treat infections, methicillin-resistant Staphylococcus, polymicrobial infections with Gram-
negative bacteria, primary or opportunistic fungi, and multidrug-resistant organisms has also
increased the difficulties in managing this patient population—and is independently a
predictor of worse outcomes and hence is often an indication for urgent surgery [7]. Advances
in the ability of microbiology labs to better identify unusual organisms—including genetic
material—have allowed for more accurately defining causative agents that otherwise would
have been considered “culture negative.” Furthermore, as more aggressive approaches to the
diagnosis and management of sepsis have resulted in a more assertive approach to insuring
appropriate and timely cultures, antibiotics, and a search of an infectious focus, there might
be a more accurate and timely diagnosis of extensive bacterial infections [8], while it is unclear
whether such an aggressive approach toward “septic” patients has changed the incidence of
endocarditis or whether the significant increase in case presentations is more of a function of
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an overall awareness. Without doubt, as resistance patterns emerge within a community and
a patient presents, for many reasons, with more unusual infectious, these patterns are also
reflected in the microbiologic picture of endocarditis. In addition, the increase in immune
modulating medications has also increased the incidence of fungal infections and very unusual
pathogens [9]. Similarly, as patients with adult congenital heart disease and prosthetic material
live longer, their overall risk of developing unusual infections that evolve into endocarditis
also increases [10, 11].
In addition, as discussed in this text, there is a growing body of literature on concepts such as
culture negative endocarditis and noninfectious endocarditis such as marantic or Libman-
Sacks endocarditis [12].
4. Diagnosis
Positive blood cultures remain the sine quo non in the diagnosis of endocarditis—but the
corollary is not always true as patients can present with significant valvular pathology and
negative cultures. The Duke Criteria, discussed at length elsewhere and in this text, remain
the cornerstones for the diagnosis of endocarditis [13]. Advances in imaging, much like
advances in the microbiologic assessment, of patients has also contributed significantly to the
diagnosis and management of infected patients [14]. While transthoracic and transesophageal
imaging are still first-line diagnostic tests to evaluate potentially infected cardiac structures—
and current guidelines help outline appropriateness criteria [2, 12]—there are growing
indications and roles for alternative imaging modalities such as the computed tomography
(CT), magnetic resonance imaging, and even 3D echocardiography [15]. As discussed in this
text—advanced imaging modalities clearly have an expanding role in the diagnosis and
management of patient with endocarditis. Early and frequent imaging can be extremely helpful
in guiding and assessing the response to therapy.
5. Therapy
As well described and discussed at length in several chapters of this book, successful man-
agement of endocarditis requires a multidisciplinary approach. Clearly targeted and appro-
priate antibiotics are necessary. Prolonged courses of intravenous antibiotics are often
prescribed, and fortunately, most patients can receive their therapies as an outpatient with
close follow-up. While social and economic variables, not to mention restrictions by insurance
companies and funding agencies, may limit options, fortunately from a medical standpoint,
most patients will tolerate a prolonged course of antibiotics.
However, the critical decision-making regarding treatment for endocarditis is focused on
appropriate interventional or surgical management. When associated with pacemaker lead
systems or intracardiac devices, especially in the setting of large vegetations and resistant
organisms or fungal infections, current guidelines advocate early and aggressive removal of
Introductory Chapter: Endocarditis - A Diagnostic and Therapeutic Challenge
http://dx.doi.org/10.5772/66406
5
all artificial material. Obviously, this can be quite challenging from not only a technical
standpoint when the patient is quite sick but also how to support a patient that may be
pacemaker-dependent in the setting of an infected pacemaker lead system. While many such
devices can be removed percutaneously, there is often concern that large vegetations or lead
systems that are firmly adherent to cardiac structures such as the tricuspid valve may require
open heart surgery with direct removal [16]. Again, such cases illustrate the importance of a
multidisciplinary team approach to not only the timing of interventions but also the specific
procedures that may be required to remove the offending hardware.
The greater challenge is the timing of surgical intervention in patients who may require valve
surgery—either repair or replacement—especially in the setting of associated other intracar-
diac pathology. Historical paradigms of prolonged courses of antibiotics and delayed surgical
intervention, often after completion of a course of antibiotics, have been challenged recently
as current European and American Society guidelines are tending to advocate early and
aggressive surgical intervention. It was believed previously that early surgery and patients
with active infections and vegetations were associated with a prohibitive risk for reinfection
and postoperative complications from operating on septic patients. This was the rationale for
delayed surgery after a prolonged course of antibiotics [17]. However, this approach was
frequently criticized as selecting only those patients who survived complication free to
complete their course of antibiotics, while potentially undertreating those patients who may
have benefited from aggressive debridement and infection source control and who ultimately
died of either overwhelming septic complications or catastrophic neurological events. A
randomized trial of 37 patients with left-sided endocarditis, severe valvular disease, and large
vegetations compared early surgical intervention with conventional medical therapies and
potential delayed interval surgery and concluded that early surgery had a significant impact
in reducing further embolic events and death [18]. Unfortunately, as a function of the nature
of the disease combined with associated comorbidities, randomized trials dealing with surgical
management of infected endocarditis can be very difficult. Current guidelines acknowledge
this fact and base their recommendations on the growing body of literature that consists
predominantly of small series and high-quality observational studies [19]. Nevertheless, the
current guidelines suggest early surgical intervention in those patients who present with the
following characteristics:
1. Valvular dysfunction resulting in signs or symptoms of acute heart failure.
2. Early surgery is recommended with those patients with fungal infections or highly
resistant organisms.
3. Those patients who present with cardiovascular complications directly associated with
their infections, including new heart block, aortic or root or annular abscess cavities, or
penetrating infectious complications such as fistula, might benefit from early surgery.
4. Surgery is indicated in the setting of persistent bacteremia or fever greater than 5–7 days
in the absence of another identifiable primary source in the setting of appropriate targeted
antibiotic therapy.
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5. Enlarging vegetations despite appropriate antibiotic therapy or evidence of recurrent
embolic complications.
6. Vegetations that are mobile and greater than 1 cm and/or with evidence of severe valve
regurgitation.
7. Mobile vegetations that are greater than 1 cm especially in the setting of other relative
indications for surgery and when involving the anterior leaflet of the mitral valve.
Similar recommendations are used to guide therapy in patients with prosthetic valve endo-
carditis [20]. However, it must be considered that overall, prosthetic valve endocarditis can be
very difficult to successfully manage medically.
A growing challenge is the population presenting with right-sided endocarditis especially in
the setting of poly-microbial or resistant organisms from intravenous drug abuse. Again,
historically because of the concerns of recurrent infections or relapse, there was reluctance to
intervene early, and many of these patients were treated medically. However, there is growing
evidence that tricuspid valve surgery should be considered in those patients with worsening
right heart failure from tricuspid regurgitation, failure of medical therapy, difficult to treat
organisms, vegetations greater than 2 cm, and worsening pulmonary complications from
presumed septic pulmonary emboli. Obviously, the challenge is not only patient selection but
also surgical timing—again emphasizing the importance of a multidisciplinary team to sort
out the clinical issues [21]. Historical management of tricuspid pathology was often “vegec-
tomy” or “valvectomy” [22]. While there were some survivors of such therapy, without doubt,
the developing of acute and chronic right heart failure and the consequences of it—such as
hepatic congestion and failure—limit the practical application of such approaches [23]. Rarely
is right-side infections managed with procedures that result in severe regurgitation—a
pathophysiology that is often the initial indication for intervention.
Nevertheless, the growing consensus is that patients with severe valvular infections especially
in the setting of failure of appropriate medical therapy, worsening vegetations, systemic
complications, and especially worsening heart failure should be promptly evaluated and
considered for early, if not urgent, surgical intervention. Obviously, the risks and benefits of
surgery in a septic patient with associated comorbidities must be evaluated on a case-by-case
basis and take into consideration vocal experiences and resources.
6. Social implications
Without doubt, the greatest challenges in dealing with patients with endocarditis are the
growing population of patients presenting with a history of intravenous drug abuse—
especially heroin. Recent data suggest a twofold increase in the number of active users of heroin
between 2006 and 2013 [24]. The growing epidemic of drug abuse, worldwide, cannot be
ignored nor denied. Endocarditis in the setting of IV drug abuse is particularly difficult to
manage, while the etiology is often the use of infected needles or contamination of the drugs
being directly injected into the vascular system. Patients who present with infections also have
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other acquired comorbidities associated with their substance abuse that challenge their
management and long-term prognosis. Hepatitis B and C as well as human immunodeficiency
virus are often encountered in this patient population [25]. Chronic pain syndromes as well as
their underlying drug addiction and associated personality and psychological disorders not
only makes this population difficult to manage in the hospital setting but also raises the concern
of long-term compliance with medical therapies. While there might be a general reluctance,
for example, to use mechanical valves in younger patients, concerns about compliance with
anticoagulation often leaves little choice. This is particularly true when patients present with
a history of hepatitis and their long-term liver function (critical for clotting factors and
Coumadin management) is unpredictable. Without doubt, this population is at risk for
recurrent problems secondary to their substance abuse history. A recent study by Kim and
colleagues illustrate the scope of this problem. Between 2002 and 2014, there was a twofold
increase in the number of patients requiring surgery for infected endocarditis at their institu-
tion space (14.8% in 2002–26% in 2012). Of the 436 patients studied, over a mean follow-up of
29 months adverse events occurred in 20% including 10% developing re-infections—often as
a function of continued substance abuse. While their findings demonstrated a lower operative
mortality in patients with drug abuse predominately as a function of their age, propensity
score analysis indicated that IV drug abuse was associated with an almost fourfold increase in
valve-related complications and a 6.2-fold increase in reinfection. Because of the concerns of
noncompliance, relapse of drug abuse, and poor socioeconomic status of many of these
patients, surgical intervention in the setting of long-standing drug abuse is often viewed as
intervening on an end-stage, often inherently fatal, disease. Some clinicians viewed attempts
at curing these patients of their infections and substance abuse as being futile. In fact, while
often discussed but rarely written, most programs will refuse surgical re-intervention except
for extenuating circumstances in those patients who continue to demonstrate ongoing drug
abuse who subsequently developed recurrent prosthetic valve infections. Prior to refusing
potentially lifesaving, but high-risk, surgery in such patients or referral to palliative care, an
open and honest discussion with an Institutional Ethics Team might be indicated.
Because of the cost of therapy that often includes prolonged hospitalizations, extensive
diagnostic evaluations, complex surgery, or multiple surgical interventions, and often a
prolonged recovery that can also be challenged by baseline comorbidities, disease complica-
tions, and access to potentially limited resources, the growing epidemic of endocarditis is
clearly a problem. This is all in the background of whether the social programs that reduce the
risk of infections, such as prophylactic antibiotics prior to dental procedures, are cost effective
or even reduce the risk of infections at all [26, 27]
7. Conclusion
As technology has improved over the years, so has the ability to detect and guide the man-
agement of patients with infections. This has also paralleled the significant increase in the
incidence of such infections as patients get older, develop more comorbidities (especially from
lifestyle choices), have more implanted devices that can potentially get infected, and have more
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procedures that might infect cardiac structures (both native and prosthetic). Endocarditis
remains a formidable problem—both in terms of diagnosis and management. Risks are high
and, without doubt, a team approach is crucial to the successful management of these patients
(Figure 1) [28, 29].
Figure 1. Components of an “Endocarditis Heart Team”—all focused on the patient.
While the goal of this text is not to be an all-inclusive reference on this topic—the hope is that
it will provide a current update on some of the key topics that reflect the multiple, evolving,
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